UNSPSC 51284009: Lymecycline

This classification denotes a tetracycline antibiotic with the molecular formula C29H38N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7D6EM3S13P, chemically known as 2-(amino-hydroxy-methylidene)-7-chloro-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione but generally known as lymecycline, which bears US NIH Compound Identifier 5280963. European Medicines Agency schedules Lymecycline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08625MIG.

UNSPSC 51284009 Lymecycline is a Commodity code covering pharmaceutical products, though recent state and local solicitations show minimal direct activity under this specific substance code. The code nominally addresses a tetracycline-class antibiotic, but the recent opportunities tagged to it in the public record reflect broader pharmaceutical and medical-supply procurement: naloxone and drug deactivation systems for public health, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. State and local buyers using these related codes include county health departments, state health and human services agencies, city fire departments, and multistate cooperative purchasing alliances that aggregate demand across state and local members.

Geographic activity spans Florida, Texas, Minnesota, and Oregon across the recent opportunities. The Seminole County, Florida IFB for naloxone and deactivation systems (IFB60459723LAS, due July 26, 2023) represents emergency-response procurement; the City of Tampa's ITB for medical and first aid supplies to the Fire Department Rescue Division (26P00145, due March 13, 2026, estimated contract value $700,000.00) shows similar demand from municipal rescue operations with a sheltered-market set-aside for certified Small Local Business Enterprises (SLBEs) and a 5 percent SLBE bid discount capped at $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) aggregates state and local facility purchasing through three authorized wholesalers and covers a two-year initial term with optional extensions. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, issued April 3, 2026) signals early-stage state interest in alternative pharmacy contracting models but does not represent a formal solicitation. Lymecycline itself appears underutilized in current state and local procurement; interest clusters instead in broader pharmaceutical supply, emergency medical consumables, and cooperative purchasing structures.